## DRUG SPECIAL AUTHORIZATION REQUEST FORM, PREFERRED PHARMACY NETWORK, AND ADHERENCE SUPPORT PROGRAM INFORMATION



## COMPLETING YOUR FORM...

To ensure prompt processing of your request, please complete the following Special Authorization Request Form in full. Note that there are sections that must be completed by you, the patient, and sections that must be completed by **your prescriber**. Once completed, submit the form to Green Shield Canada (GSC) via your method of choice:

By email:	drugspecial.autho@greenshield.ca		
By fax:	1.866.797.6483		
By mail:	Green Shield Canada, Drug Special Authorization Department		
	P.O. Box 1606, Windsor ON N9A 6W1		

## Note that submission of an incomplete form may result in delays.

Your request will be reviewed and evaluated by our Drug Special Authorization Department who will share the results with you. Should you have any questions, call GSC's Contact Centre at 1.888.711.1119.

## OTHER DRUG COVERAGE...

If you are eligible for coverage by another plan (public or private), indicate that in Section 1B of the authorization form.

If you have provincial drug coverage, please ensure that your prescriber has applied for coverage under your primary provincial drug plan. The result of that application must be attached to the completed Special Authorization Request Form.

## PREFERRED PHARMACY NETWORK (PPN)

If your request for coverage is approved, you may be required to obtain your special authorization drug at an approved pharmacy. If this applies to your benefits plan, a care coordinator working on behalf of GSC will contact you to help you find an approved pharmacy near you. The care coordinator will also work with you and your physician to arrange to have your prescription sent to the pharmacy you select.

Should you choose not to speak with the care coordinator, and you obtain your special authorization drug at an unapproved pharmacy, your claim may not be paid under your benefits plan.

## ADHERENCE SUPPORT PROGRAM

Some drug treatment plans are complicated, and patients can sometimes find it difficult to follow their prescriber's instructions when taking their medication. If your special authorization drug is approved, you may be eligible for adherence support services. A medication management specialist can work with you to ensure that you have the support necessary to take your medication as instructed and adhere to your drug treatment plan.



# PRESCRIPTION DRUG SPECIAL AUTHORIZATION REQUEST FORM

Please note: Incomplete information may delay your request for processing.

SECTION 1A – PATIENT INFORMATION First Name			Green S	Green Shield ID		Employer Name		
Last Name	Last Name			Date of	Date of Birth (YYYY/MM/DD)		Email Address	
Street Addres	S					Teleph	one (Home)	
City	Province			Postal (	Postal Code		Telephone (Mobile)	
<b>SECTION 1B</b>	- COORDINA	TION OF	BENEFITS					
	Is the patient enrolled in any assistance program for the requested drug?							
Patient Support	Program Name Patient Identifier							
Program	Contact First	Name	Contact La	st Name	Contact Phone		Contact Email	
	Is the patient	in contact	with an alte	rnate drug a	access navigator	<sup>.</sup> (i.e., ho	ospital)? 🛛 Yes 🗆 N	lo
Drug Access	Organization Name							
Navigator	Contact First	Name	Contact La	st Name	Contact Phone		Contact Email	
Provincial	Has the patient applied for reimbursement under a provincial plan? $\Box$ Yes $\Box$ No $\Box$ NA							
Coverage	What is the coverage decision? (Attach decision outcome letter)							
	Is this patient covered by any other plan? (If yes answer below) $\Box$ Yes $\Box$ No $\Box$ NA							
Other Private	Planholder First Name			Planholder	Last Name	Date of Birth (YYYY/MM/DD)		
Coverage	Relationship to Planholder							
		overage d	ecision? (At	tach outcom	e letter if receive	ed) □/	Approved 🛛 Denied	
SECTION 1C		ed nhysicia	n/dentist m	edical practit	ioner hospital n	atient as	sistance program, clini	ic
request. I here as required, in (PPN) vendor my personal in where applicat I acknowledge purposes and health related claim and that at any time by I understand the within Canada	by authorize G cluding any hea working with G formation is ne ble, to administ that my persor may include inf information. I a refusing to con sending writter nat personal inf only when the <u>n. I certify that t</u>	reen Shiel alth care p reen Shiel eeded to as er pharma nal information a cknowledg isent may in n instructio formation n informatio	d Canada to rovider, patie d Canada for sess eligibili cy preferred tion may be about my dru- te that provid result in dela ns to that effi- nay be subje n is needed to	obtain and e ent assistance the purpose ty for this dru provider network exchanged a g claims, dia ling my conse y or denial or ect at the add ct to disclosu to administer	exchange persona e program and/or e of administering ug, to administer work and patient and transferred be gnosis, medical of ent will help Gree f my claim. This of dress indicated b ure to those author this benefit and/or	al information preferrent this ben the group support p etween the condition en Shield consent r elow. prized un or to con o the bes	ealth as it relates to thi ation with other parties ed pharmacy network hefit. I acknowledge that p benefits plan, and programs on my behal hese parties for these , treatment, and other I Canada to assess my may be revoked by me ader applicable law firm the accuracy of at of my knowledge. (YYYY/MM/DD)	s at If. V
If under 16 years	of ane (1/ years	of age in Or	iehec) the sign	nature of the n	arent / quardian is re	auired		



# PRESCRIPTION DRUG SPECIAL AUTHORIZATION REQUEST FORM Please note: Incomplete information may delay your request for processing. SECTION 2A – DRUG REQUESTED FOR EVALUATION Product Name and Strength

Dose		Frequency	of Administratio	n			
Route (ex. oral, IV, etc.)	Therapy D	Therapy Duration					
Is the patient currently on the (If yes provide therapy start da		□ Yes □ No Therapy Start (YYYY/MM/DD)					
If already established on thera established on therapy throug on initiation of therapy. SECTION 2B – LOCATION C	h compassionate coverage			0			
		enters pleas	se complete inf	ormation below			
□ Physician's Office □ Hospital (In-Patient)	Name and Address of Inf						
□ Hospital (Out-Patient) □ Infusion Center	City	Province		Postal Code			
SECTION 2C – DIAGNOSIS	AND COMMENTS						
Diagnosis		Dia	agnostic Code (i.	e. ICD-10)			
SECTION 2D – CURRENT/PREVIOUS TREATMENT FOR DIAGNOSIS							
Patient has not tried other	r therapies for this diagnos	is (skip Secti	ion 2D)				
Drug/Regimen #1	Start	(YYYY/MM/DD)	End (YYYY/MM/D				
Dose / Frequency / Details				☐ Intolerance (explain) ☐ Other (explain)			
Drug/Regimen #2	Start	(YYYY/MM/DD)	End (YYYY/MM/D	<sup>D)</sup> □ Lack of Response			
Dose / Frequency / Details				<ul> <li>☐ Intolerance (explain)</li> <li>☐ Other (explain)</li> </ul>			
Drug/Regimen #3	Start	(YYYY/MM/DD)	End (YYYY/MM/D	· · · /			
Dose / Frequency / Details	<ul> <li>☐ Intolerance (explain)</li> <li>☐ Other (explain)</li> </ul>						
Additional information on curre	ent, previous or required tr	eatment for o	diagnosis (attach				

## PRESCRIPTION DRUG SPECIAL AUTHORIZATION REQUEST FORM



Please note: Incomplete information may delay your request for processing.

First Name	License Number	Specialty			
Last Name	Telephone	Fax			
Street Address					
City	Province	Postal Code			
Signature		Date (YYYY/MM/DD)			
SECTION 3B – SUBMISSION INSTRUCTIONS					
Return request form along with any ori	ginal paid "Official Pharmacy" rec	ceipts to :			
<b>Fax</b> : 1.519.739.6483 or	Mail: Green Shie	Mail: Green Shield Canada			
1.866.797.6483	Drug Special Au	Drug Special Authorization Department,			
Email: drugspecial.autho@greenshie	eld.ca P.O. Box 1606, V	P.O. Box 1606, Windsor ON N9A 6W1			

COST OF OBTAINING THIS INFORMATION IS AT THE EXPENSE OF THE PATIENT/PLAN MEMBER.

# **ELIGIBLE CRITERIA**



ALPHAGAN-P / ALPHAGAN (e.g. BRIMONIDINE TARTRATE)

Please present this Eligible Criteria sheet to your <u>physician</u> to use as <u>reference</u> when completing the Special Authorization Request.

### ELIGIBLE CRITERIA

As first-line treatment of elevated intraocular pressures in patients who cannot tolerate an ophthalmic beta- blocking agent or where beta-blocking agents are contraindicated. (OR)

As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents. (OR)

For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.

These drugs may have the potential for other uses outside of the indications identified, but are only eligible benefits of the controlled formularies under the conditions specified and with the proper documentation.